Treatment of central precocious puberty with depot leuprorelin

Abstract

We evaluated the pituitary and gonadal suppression in 40 girls and nine boys treated with depot leuprorelin (3.75 mg sc if body weight > or = 20 kg, 1.87 mg if body weight < 20 kg) every 28 days for central precocious puberty. Gonadal suppression was obtained in most of the children with this dose: 3 months after initiation of the treatment, 85% of children had a peak plasma luteinizing hormone response to gonadotropin-releasing hormone < 3 IU/l and the gonadal axis remained suppressed throughout the duration of the study (up to 24 months). Four patients required higher doses of leuprorelin to achieve suppression. In two girls, a cutaneous reaction to the drug was associated with incomplete suppression and the treatment had to be interrupted. Plasma leuprorelin levels tended to increase from day 3 to day 28 after injection. Residual leuprorelin levels measured 28 days after injection were stable during the first year of the study. We conclude that an initial dose of depot leuprorelin of 3.75 mg sc every 28 days is efficient in most children with central precocious puberty.

Long-Term Suppression of Pituitary-Gonadal Function with Three-Month Depot of Leuprorelin Acetate in a Girl with Central Precocious Puberty

“…The hormonal monitoring in our patient showed constant pituitary-gonadal suppression of a comparable degree as seen in patients treated with the 1-month leuprorelin depot [4, 5]or other GnRH agonists such as triptorelin [19]. The return to normal size for age of the uterus and ovaries was also comparable to treatment with 1-month depots of various GnRH agonists [4].…”

“…In a randomized study, patients with CPP treated with depot triptorelin attained a mean final height above their mean target height, whereas patients treated with short-acting buserelin did not [3]. One-month depot preparations are available for the GnRH agonists leuprorelin [4, 5], triptorelin [6]and goserelin [7]. All have been shown to be effective in suppressing the pituitary-gonadal axis.…”

Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty

“…Subcutaneous intolerance to depot GnRH agonists has been reported and is mostly due to reaction to the lactide-coglycolide polymer (9,11,16,26,27). In the present study, mild-to-moderate local reactions at the injection site were reported in 8% of the children, and injection pain in only 3%.…”

Santral Puberte Prekoks Tanılı Bir Çocukta Triptorelin Asetat İlişkili Anafilaksi: Olgu Sunumu

“…Triptorelin (Decapeptyl® Depot) ve Leuprolid (Lucrin Depot®) asetat tedavide kullanılan başlıca GnRH analoglarıdır. Önerilen doz Leuprolid asetat için 150-300 mcg/kg/ay (3.75-7.5 mg/ay), Triptorelin için ise 100-150 mcg/kg/aydır (3,4,5).…”